Chimerix
CMX157
CMX157 leverages our PIM (Phospholipid Intramembrane Microfluidization) Conjugate Technology with tenofovir, the molecule underlying the prodrug Viread®, an antiviral agent approved for the treatment of human immunodeficiency virus (HIV) and chronic hepatitis B.
We are developing CMX157 for the treatment of HIV infections. With increased in vitro activity against HIV (>250-fold reduction in IC50 versus tenofovir), CMX157 produces substantially more active antiviral in target cells and greatly improved activity against nucleoside reverse transcriptase inhibitor (NRTI)-resistant HIV in in vitro testing. In vivo toxicology studies show that high plasma levels of CMX157 can be achieved with minimal toxicities, indicating an encouraging safety profile for the compound.
Clinical Trials
himerix has completed a Phase 1 clinical study of orally-administered CMX001 in 84 healthy volunteers. The blinded, randomized, parallel-group, placebo-controlled study evaluated the safety and pharmacokinetics of single and multiple doses of CMX001. CMX001 was well tolerated at all doses. In addition, CMX001 was well absorbed after oral dosing, with dose-dependent pharmacokinetics. Read More
Licensing Opportunities
Chimerix has amassed an unusual breadth of assets with considerable potential in antiviral innovation, including our PIM (Phospholipid Intramembrane Microfluidization) Conjugate Technology and the Townsend Chemical Library. The combination of our team’s internal antiviral product expertise with a number of internally-generated leads against several important viruses allows us the flexibility to pursue out-licensing or co-development partners for our emergent antiviral medicines. Read More